Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy

International Journal of Cardiology

Volumn 114, Issue 2, 2007, Pages 210-217

  Kasai, Takatoshi ^a   Miyauchi, Katsumi ^a   Kurata, Takeshi ^a   Satoh, Hitoshi ^a   Ohta, Hiroshi ^a   Tanimoto, Kosei ^a   Kawamura, Masaki ^a   Okazaki, Shinya ^a   Yokoyama, Ken ^a   Kojima, Takahiko ^a   Akimoto, Yoshinori ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Long term; Mortality; Percutaneous coronary intervention; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG USE; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33751322472     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.01.028     Document Type: Article

References (19)

1. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333 (1995) 1301-1307
2. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
4. Sever P.S., Dohlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361 (2003) 1149-1158
5. Scandinavian Simvastatin Suvival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
6. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Event Trial Investigators. N Engl J Med. 335 (1996) 1001-1009
7. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339 (1998) 1349-1357
8. Serruys P.W., de Feyter P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. JAMA 287 (2002) 3215-3222
9. Strandberg T.E., Pyrl K., Cook T.J., et al. Mortality and incidence of cancer during 10-year follow-up of Scandinavian Simvastatin Survival Study (4S). Lancet 364 (2004) 771-777
10. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360 (2002) 1623-1630
11. Chan A.W., Bhatt D.L., Chew D.P., et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105 (2002) 691-696
12. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 127 (1997) 757-763
13. Bjerre L.M., and LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 110 (2001) 716-723
14. Iso H., Jacobs D.R., Wentworth D., Neaton J.D., and Cohen J.D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320 (1989) 904-910
15. Lee S.H., Bae H.J., Yoon B.W., Kim H., Kim D.E., and Roh J.K. Low concentration of serum total cholesterol is associated with multifocal signal loss lesion on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesion. Stroke 33 (2002) 2845-2849
16. Weintraub W.S., Boccuzzi S.J., Klein J.L., et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 331 (1994) 1331-1337
17. Serruys P.W., Foley D.P., Jackson G., et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. Eur Heart J 20 (1999) 58-69
18. Walter D.H., Fichtlscherer S., Britten M.B., et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 38 (2001) 2006-2012
19. Walter D.H., Sch chinger V., Elsner M., Mach S., Auch-Schwelk W., and Zeiher A.M. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 85 (2000) 962-968